申请人:Boehringer Ingelheim GmbH
公开号:US03992535A1
公开(公告)日:1976-11-16
Compounds of the formula ##SPC1## Wherein R.sub.1 is hydrogen, methyl or ethyl, and Ar is phenyl, 3-chlorophenyl, 3-bromophenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 3-tolyl, 2-methoxyphenyl, 3-methoxyphenyl, 2-pyridyl, 4-methyl-2-pyridyl, 6-methyl-2-pyridyl, 3-hydroxy-2-pyridyl, 3-pyridyl, 4-pyridyl, 6-chloro-3-pyridazinyl, 2-pyrazinyl, 6-chloro-2-pyrazinyl, 6-chloro-4-pyrimidinyl, 2-thiazolyl, 4-methyl-2-thiazolyl, 4-ethyl-2-thiazolyl, 5-methyl-2-thiazolyl, 5-ethyl-2-thiazolyl, 4,5-dimethyl-2-thiazolyl, 4-ethyl-5-methyl-2-thiazolyl, 5-ethyl-4-methyl-2-thiazolyl, 2-benzothiazolyl, 4,5,6,7-tetrahydro-2-benzothiazolyl, 5,6-dihydro-7H-thiopyrano[4,3-d]thiazol-2-yl, 3-methyl-5-isothiazolyl, 1,3,4-thiadiazolyl, 5-methyl-1,3,4-thiadiazol-2-yl or 5-methyl-3-isoxazolyl, And non-toxic, pharmacologically acceptable salts thereof formed with an inorganic or organic base; the compounds as well as their salts are useful as inhibitors of platelet adhesion and aggregation.
式##SPC1##的化合物,其中R1为氢、甲基或乙基,Ar为苯基、3-氯苯基、3-溴苯基、2-氟苯基、3-氟苯基、4-氟苯基、3-甲苯基、2-甲氧基苯基、3-甲氧基苯基、2-吡啶基、4-甲基-2-吡啶基、6-甲基-2-吡啶基、3-羟基-2-吡啶基、3-吡啶基、4-吡啶基、6-氯-3-哒嗪基、2-嘧啶基、6-氯-2-嘧啶基、6-氯-4-嘧啶基、2-噻唑基、4-甲基-2-噻唑基、4-乙基-2-噻唑基、5-甲基-2-噻唑基、5-乙基-2-噻唑基、4,5-二甲基-2-噻唑基、4-乙基-5-甲基-2-噻唑基、5-乙基-4-甲基-2-噻唑基、2-苯并噻唑基、4,5,6,7-四氢-2-苯并噻唑基、5,6-二氢-7H-噻喃并[4,3-d]噻唑-2-基、3-甲基-5-异噻唑基、1,3,4-噻二唑基、5-甲基-1,3,4-噻二唑-2-基或5-甲基-3-异噁唑基,以及与无机或有机碱形成的无毒、药学上可接受的盐;这些化合物及其盐可作为血小板粘附和聚集的抑制剂。